ReviewFrontiers in pediatrics2025
Global, regional and national trends in the burden of persistent pulmonary hypertension of the newborn and essentials of its management from 1993 to 2023: a scoping review.
Review in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Melatonin effects on the left ventricular function in neonates with persistent pulmonary hypertension.European journal of pediatrics · 2026Trial
- Persistent Pulmonary Hypertension of the Newborn: A Pragmatic Review of Pathophysiology, Diagnosis, and Advances in Management.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Persistent pulmonary hypertension of the newborn (PPHN) is a frequent neonatal emergency in the neonatal intensive care unit ( Objective: This scoping review was undertaken to provide a global overview of several key aspects: (1) the prevalence/incidence and etiologies of PPHN, (2) the mortality rate linked to PPHN during hospitalization and the primary causes of such mortality, (3) the risk factors related to PPHN, and (4) the approaches to managing PPHN. The aim of this scoping review was not to assess the methodological soundness of the identified studies, but instead to deliver a broad, comprehensive perspective on PPHN, identify gaps within the current literature, and outline potential avenues for future research. The results are anticipated to assist in developing public health strategies aimed at reducing the morbidity and mortality tied to PPHN globally. Methods: We conducted a digital search in MEDLINE and the Cochrane Library, from January 1, 1993 to December 31, 2023.We incorporated observational studies, interventional studies, and reviews that provided adequate data on the incidence/prevalence, mortality rates, predictors, etiological factors, diagnosis, and management of PPHN among the general neonatal population (age 0-28 days old). This procedure followed the guidelines set by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extensions for Scoping Reviews (PRISMA-ScR). Additionally, we utilized the methodological framework for scoping reviews as outlined by Arksey and O'Malley, which consists of formulating the research question, conducting a search for pertinent studies, selecting the studies, organizing the data, and compiling, summarizing and reporting the findings. Results: A total of 128 research articles were collected from 27 countries categorized as either high-income or low- and middle-income countries (LMICs). The prevalence of PPHN ranges from 0.1%-8.1% in the different study populations. The highest global prevalence rates are observed in Europe and Asia, while lower prevalence rates are reported in the Americas and Africa. Neonatal infections are the leading cause of PPHN in Asia and the Americas, whereas meconium aspiration syndrome predominates in Europe. Several independent risk factors for PPHN include premature birth, male sex, ethnicity, extremes of birth weight, advanced maternal age, maternal obesity, multiple births, maternal smoking, pregestational/gestational diabetes mellitus, infectious history, caesarean delivery, antenatal drug exposure, fetal distress, APGAR score and meconium-stained amniotic fluid. The PPHN-related in-hospital mortality rate associated with PPHN ranges from 3.0%-57.9%, with the highest rates reported in Asia and the lowest in the United States of America (USA) and the United Kingdom (UK). It is advised that clinical evaluation incorporates the oxygenation index (OI) to assist in guiding medical practice. Conclusion: PPHN has a high global burden, driven by neonatal infections and meconium aspiration syndrome, particularly pronounced in LIMCs where there is a pressing need for more intensive treatments and innovative solutions, ideally supported by region-specific subsidies, to address this concerning burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.